These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 25629154)

  • 41. Problems encountered in the pharmacovigilance of violence and aggression.
    Prescrire Int; 2014 Jun; 23(150):154. PubMed ID: 25121149
    [No Abstract]   [Full Text] [Related]  

  • 42. [Estimation of the intake of food additives--methods applied in the European Union].
    Szponar L; Traczyk I; Jarzebska M; Stachowska E
    Rocz Panstw Zakl Hig; 2003; 54(4):363-71. PubMed ID: 15052734
    [TBL] [Abstract][Full Text] [Related]  

  • 43. What influences referrals within community palliative care services? A qualitative case study.
    Walshe C; Chew-Graham C; Todd C; Caress A
    Soc Sci Med; 2008 Jul; 67(1):137-46. PubMed ID: 18433963
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?
    Trifirò G; Pariente A; Coloma PM; Kors JA; Polimeni G; Miremont-Salamé G; Catania MA; Salvo F; David A; Moore N; Caputi AP; Sturkenboom M; Molokhia M; Hippisley-Cox J; Acedo CD; van der Lei J; Fourrier-Reglat A;
    Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1176-84. PubMed ID: 19757412
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Primary care physician specialty referral decision making: patient, physician, and health care system determinants.
    Forrest CB; Nutting PA; von Schrader S; Rohde C; Starfield B
    Med Decis Making; 2006; 26(1):76-85. PubMed ID: 16495203
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The EU-ADR Web Platform: delivering advanced pharmacovigilance tools.
    Oliveira JL; Lopes P; Nunes T; Campos D; Boyer S; Ahlberg E; van Mulligen EM; Kors JA; Singh B; Furlong LI; Sanz F; Bauer-Mehren A; Carrascosa MC; Mestres J; Avillach P; Diallo G; Díaz Acedo C; van der Lei J
    Pharmacoepidemiol Drug Saf; 2013 May; 22(5):459-67. PubMed ID: 23208789
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Impact of the referral letter on triage decisions in adult patients admitted to the emergency department].
    Chauveau P; Mazet-Guillaume B; Baron C; Roy PM; Tanguy M; Fanello S
    Sante Publique; 2013; 25(4):441-51. PubMed ID: 24404726
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Nutrition and health--safety of new types of food].
    van de Wiel JA; van Rossum CM; Rutgers M
    Ned Tijdschr Geneeskd; 2004 Jan; 148(1):12-7. PubMed ID: 14750449
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Major milestones for European pharmaceutical policy].
    Sauer F
    Rev Hist Pharm (Paris); 2014 Jan; 62(381):61-74. PubMed ID: 25668913
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacovigilance-related topics at the level of the International Conference on Harmonisation (ICH).
    Bahri P; Tsintis P
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):377-87. PubMed ID: 15517542
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Implications of the Pharmacovigilance Risk Assessment Committee recommendations for the treatment of genitourinary syndrome.
    Buttigieg GG; Micallef-Stafrace K
    Br J Hosp Med (Lond); 2021 Mar; 82(3):1-3. PubMed ID: 33792390
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Increasing the impact of Post Authorisation Safety Studies: transparency is key.
    Kurz X; Arlett P; Eichler HG; Nolte A; Straus S; Rasi G
    Eur J Intern Med; 2021 Jan; 83():6-7. PubMed ID: 33277138
    [No Abstract]   [Full Text] [Related]  

  • 53. Pharmacovigilance Symposium ISCR Annual Conference Jan 5, 2013: Safety aspects of hard endpoint or outcome trials.
    Suvarna V; Nambiar I; Mukherjee S; Mallath MK
    Perspect Clin Res; 2013 Apr; 4(2):148-52. PubMed ID: 23833742
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Not Available].
    Lamarque V; Merle L; Demarez JP;
    Therapie; 2008; 63(4):301-9. PubMed ID: 27392547
    [No Abstract]   [Full Text] [Related]  

  • 55. European pharmacovigilance: increasingly outsourced to drug companies.
    Prescrire Int; 2014 Dec; 23(155):302-3, 305-7. PubMed ID: 25629153
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
    Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
    Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A description of medicines-related safety issues evaluated through a referral procedure at the EU level after 2012.
    Farcas A; Balcescu T; Anghel L; Bucsa C; Mogoșan C
    Expert Opin Drug Saf; 2020 Jun; 19(6):755-762. PubMed ID: 32186202
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
    Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
    Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety referral procedures clarified.
    Prescrire Int; 2014 Dec; 23(155):304-5. PubMed ID: 25629154
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.